Form 4: GoodRx Director Kelly Kennedy Receives Equity Grant

GoodRx Holdings, Inc. director Kelly J. Kennedy was granted 73,434 restricted stock units as part of standard equity compensation.

Summary

• Director Kelly J. Kennedy acquired 73,434 restricted stock units (RSUs) of Class A common stock.
• The transaction occurred on June 16, 2026.
• The RSUs represent a contingent right to receive one share of Class A common stock per unit.
• Following this transaction, the director's total beneficial ownership is 207,645 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on company operations or financial strategy.

Positives

• The equity grant aligns the director's interests with long-term shareholder value.

Negatives

• The issuance of new equity results in minor dilution to existing shareholders.

Risks

• Vesting is subject to the director's continued service through the vesting date.

Future Outlook

The RSUs vest in full on the earlier of the one-year anniversary of June 16, 2026, or the date of the 2027 Annual Meeting of Stockholders.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard corporate governance practice to ensure alignment with shareholder interests in the healthcare technology sector.

Comparison to Industry Standards

• The grant of RSUs to directors is consistent with standard compensation practices for publicly traded companies of similar market capitalization.
• The vesting schedule of approximately one year is standard for annual director equity awards.

Stakeholder Impact

• Minor dilution for existing shareholders due to the issuance of new equity.

Next Steps

• Vesting of the 73,434 RSUs on the earlier of June 16, 2027, or the 2027 Annual Meeting of Stockholders.

Key Dates

Keywords

GoodRx, GDRX, Insider Trading, Form 4, Equity Compensation, Director Compensation